Zacks Research Has Bearish Forecast for BHC Q1 Earnings

Bausch Health Companies Inc. (NYSE:BHC - Free Report) - Equities research analysts at Zacks Research cut their Q1 2025 earnings per share (EPS) estimates for Bausch Health Companies in a report released on Tuesday, March 11th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $0.80 per share for the quarter, down from their prior forecast of $0.87. The consensus estimate for Bausch Health Companies' current full-year earnings is $4.41 per share. Zacks Research also issued estimates for Bausch Health Companies' Q4 2025 earnings at $1.27 EPS, FY2025 earnings at $4.26 EPS, Q2 2026 earnings at $1.10 EPS and Q3 2026 earnings at $1.28 EPS.

Bausch Health Companies (NYSE:BHC - Get Free Report) last posted its earnings results on Wednesday, February 19th. The company reported $1.21 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.44). Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 577.82%. The firm had revenue of $2.56 billion during the quarter, compared to analyst estimates of $2.51 billion.

Several other brokerages have also recently issued reports on BHC. Jefferies Financial Group reiterated a "hold" rating and issued a $8.00 price target (down from $12.00) on shares of Bausch Health Companies in a research note on Thursday, February 6th. Royal Bank of Canada cut their price target on Bausch Health Companies from $11.00 to $10.00 and set a "sector perform" rating for the company in a research note on Thursday, January 30th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $7.42.

Remove Ads

Bausch Health Companies Stock Down 0.5 %

Shares of Bausch Health Companies stock traded down $0.04 on Friday, hitting $7.01. The stock had a trading volume of 929,139 shares, compared to its average volume of 2,698,682. Bausch Health Companies has a twelve month low of $3.96 and a twelve month high of $11.46. The business's 50 day moving average is $7.20 and its two-hundred day moving average is $7.67. The stock has a market cap of $2.58 billion, a price-to-earnings ratio of -58.37, a price-to-earnings-growth ratio of 0.37 and a beta of 0.59.

Institutional Investors Weigh In On Bausch Health Companies

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Mountain Hill Investment Partners Corp. bought a new stake in Bausch Health Companies during the fourth quarter worth $56,000. Bank of Nova Scotia bought a new position in shares of Bausch Health Companies in the 4th quarter valued at $83,000. One68 Global Capital LLC bought a new position in shares of Bausch Health Companies in the 4th quarter valued at $90,000. Balyasny Asset Management L.P. bought a new position in shares of Bausch Health Companies in the 4th quarter valued at $97,000. Finally, Alpine Global Management LLC bought a new position in shares of Bausch Health Companies in the 4th quarter valued at $114,000. 78.65% of the stock is currently owned by institutional investors.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.